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Abstract
Purpose Pulmonary hypertension (PH) due to COPD has
dismal prognosis. We reviewed the long-term effect of PH-
target therapy in severe PH-COPD.
Method Patients attending our PH-clinic were reviewed
for PH-COPD receiving PH-target therapy. Baseline char-
acteristics, death/transplantation until 2014, therapy,
NYHA functional class, 6 min walk distance (6MWD) and
oxygen saturation (SpO2) at baseline, 3, 6, 12 and
24 months were analysed.
Results Of 48 PH-COPD identified 21 were excluded
(insufficient data, comorbidity). 27 patients (7 females, 21
smokers, 23 emphysema) with median (quartiles) baseline
age 70 (60; 76) years, FEV1 60 (46; 78) %, FEV1/FVC 57
(51; 64) %, DLCO 42 (36; 59) %, mean pulmonary artery
pressure 39 (32;44) mmHg under inhaled iloprost (10),
subcutaneous prostanoids (2), intravenous prostanoids (3),
endothelin receptor antagonists (15) and phosphodiester-
ase-5-inhibitors (25) were included. Under therapy, NYHA
functional class improved from 3.5 (3; 4) to 3 (2; 4) after
3 months and 3 (2; 3.5) after 6 months (p = .02 and .008).
The 6MWD improved from 373 (236; 452) to 395 (339;
472), 414 (285; 492) and 396 (308; 497)m at 3, 6 and
12 months (p = .005, .006 and .011) with unchanged
resting-SpO2 but decreased peak-exercise SpO2. During
median follow-up of 5.9 (2.3; 8.4) years, 10 died, 2 were
transplanted and 2 were lost to follow-up. Transplant-free
survival at 1,2,3 years was 92,69,54 % and was similar for
GOLD stages 1–4, but worse for patients with mPAP
C40 mmHg (p = .026), 6MWD \370 m (p = 0.008),
resting SpO2 \92 % (p = 0.02) and peak-walk SpO2
\87 % (p = 0.012).
Conclusion PH-target vasodilator therapy improved
NYHA functional class and 6MWD up to one year in
highly selected patients with severe PH-COPD. Poor
exercise capacity, low SpO2 and high mean pulmonary
artery pressure at baseline but not airflow obstruction were
associated with unfavourable outcome.
Keywords Pulmonary hypertension  Chronic obstructive
pulmonary disease  Vasodilator therapy
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Introduction
Pulmonary hypertension (PH) is defined by the World
Health Organisation (WHO) as a mean pulmonary artery
pressure (mPAP) C25 mmHg at rest during right heart
catheterization (RHC) and is classified into 5 major groups
[1, 2]. After PH due to left heart diseases, PH due to
chronic lung diseases is most common and within this,
chronic obstructive pulmonary disease (COPD) is the most
frequent cause owing to the high prevalence of COPD
worldwide [3]. COPD is defined as a slowly progressive
systemic disease, characterized by a fixed airflow
obstruction by spirometry [4]. COPD has been classified by
the global initiative for chronic obstructive lung disease
(GOLD) in 4 categories according to the forced expiratory
volume in 1 s (FEV1) [5]. According to the WHO, 210
million people are affected by COPD worldwide and it was
estimated that around 3 million people died of COPD,
which corresponds to 5 % of all deaths globally [3, 5].
Thus, COPD is a leading cause of morbidity worldwide and
will become the fourth cause of mortality in 2030 [3]. The
main cause of COPD is certainly cigarette smoking,
especially in the western world, but also indoor and out-
door air pollution, occupational dusts and alpha-1-anti-
trypsin deficiency are important risk factors [3, 4].
Mild and typically exercise-induced PH is frequently
found in COPD with increasing prevalence with more severe
airflow limitation and PH in COPD is especially associated
with chronic hypoxemia [6–8]. The prevalence of PH due to
COPD (PH-COPD) is not well known, mainly as RHC is not
done routinely and the prevalence may vastly vary according
to the setting (ambulatory, general practitioners vs. specialist
centres with severe cases). Despite PH-COPD usually being
mild (mPAP \30 mmHg), some patients develop a severe
and rapidly progressive PH (mPAP C35 mmHg) leading to
death or necessitating lung transplantation [8–10]. The latter
are sometimes called ‘‘out of proportion’’ cases, although
this terminology has never been standardized and is aban-
doned by some experts [9]. It is important to know, that the
severity of airflow obstruction does not correlate with the
mPAP and thus, PH might be observed with mild airflow
limitation [7, 9]. PH in COPD is a significant risk factor for
hospitalization, for acute exacerbation and is associated with
a worse survival [11, 12]. Main pathogenetic mechanisms
involved in PH-COPD are hypoxic pulmonary vasocon-
striction, remodelling of pulmonary vessels, inflammation,
pulmonary microthrombosis and the reduction in the number
of pulmonary vessel in emphysema [6, 13].
Up to now, there is no specific therapy for PH-COPD
[9]. According to pathogenesis, smoking cessation, long-
term oxygen therapy and treatment of airflow obstruction
by inhalation therapy or treatment of right heart failure by
diuretics are therapeutic cornerstones [9]. Treatment with
vasodilator therapy as used for pulmonary arterial hyper-
tension, namely prostanoids, endothelin receptor antago-
nists (ERA) and phosphodiesterase-5-inhibitors (PDE5I), is
not recommended due to the lack of randomized controlled
trials and the fear that they may impair gas exchange due to
pulmonary vasodilation and increased ventilation–perfusion
mismatch [9, 14]. On the other hand, favourable antipro-
liferative and vasodilator effects of PH-target therapy
(prostanoids, ERA and PDE5I) might be of value in some
patients with severe PH-COPD in order to reduce the
afterload of the right heart, in analogy to other forms of PH
[9, 15]. In lack of RCT, the aims of the present study were
to identify all patients with PH-COPD who received PH-
targeted therapy for at least 3 months, to look at changes in
exercise performance, quality of life (QoL), functional
class, hemodynamic, blood oxygenation, safety and event-
free survival with these therapies.
Methods
Patients
Datasets of all patients attending our PH-outpatient clinic
were reviewed, in this retrospective data analysis, to
identify patients with PH-COPD. Patients were included if
they had PH defined as mPAP C25 mmHg with a pul-
monary artery wedge pressure (PAWP) B15 mmHg during
right heart catheterisation along with a diagnosis of COPD
defined as FEV1/FVC \0.7 and if PH-target therapy had
been started and taken for at least 3 months. PH-target
therapy was defined as parenteral prostanoids, ERA and
PDE5I. Patients were excluded if they had another reason
for their PH, namely chronic left heart disease (PAWP
C15 mmHg), thromboembolic PH, PH associated with
connective tissue diseases, interstitial or other significant
parenchymal lung disease at high resolution thoracic CT,
other PH classification (HIV, drugs- and toxins) or a
combination of these. The outpatient clinic database was
searched to identify cases diagnosed with PH from January
2000 to end of December 2013. The study was approved by
988 Lung (2014) 192:987–995
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the Cantonal ethical review board Zurich (KEK-2013-
0553).
Data Retrieval, Analysis and Statistics
All patients’ records were thoroughly reviewed and the
following characteristics and parameters noted at baseline
just before the start of PH-target therapy: age, sex, smoking
status and history, pulmonary function test, the presence of
emphysema at chest computed tomography, pulmonary
hemodynamics by right heart catheterisation and echocar-
diography, haemoglobin, NT-pro-brain natriuretic peptide
(NT-pro-BNP), 6MWD, New York Heart Association
(NYHA) functional class and QoL (Minnesota living with
heart failure questionnaire;MLHF).
According to the practice at our PH-clinic, patients
under PH-target therapies have regular follow-up visits at
3, 6, 12 and 24 months and at least yearly thereafter with
assessments of 6MWD, NYHA class, MLHF and NT-pro-
BNP. This close follow-up allowed having complete fol-
low-up (defined as death or lung transplantation).
Descriptive statistics for median (quartiles) were used,
and analysis of variance for repeated measures (Friedman-
test) and Wilcoxon matched pair tests were used to com-
pare baseline values with values after 3, 6, 12 and
24 months of therapy. Event-free survival was calculated
by Kaplan-Meier analysis over all PH-COPD patients and
stratified by disease severity, namely by GOLD-classes, the
medians of mPAP or SpO2 at rest and peak-walk. Cox
regression was used to look for the predictive value of
baseline valuables or changes with therapy after 3 months.
Pearson’s correlation between PH and COPD was calcu-
lated. A p \ 0.05 was considered significant.
Results
From 493 PH-datasets, 48 were classified as PH-COPD. 21
had to be excluded due to diagnostic failure, comorbidity
or no PH-target therapy (Fig. 1). Characteristics of 27
included patients are shown in Table 1. 3/4 of patients were
male smokers (1/5 persistent) and severely limited (half in
NYHA class IV) with a markedly reduced 6MWD. Airflow
limitation was comparably mild with a median FEV1 of
60 % and the majority being in Gold stage I or II,
emphysema was documented in 92 %. Pulmonary hemo-
dynamics were severely compromised [mPAP of 39 (32;
44) mmHg]. Most patients had single bronchodilator ther-
apy; inhaled steroids were used in half. 60 % of patients
used supplemental oxygen at least during nights, 89 %
were anticoagulated. The NT-pro-BNP was elevated [653
(159; 1,194) ng/l, normally \300 ng/l]. We found no
correlation between COPD severity according to baseline
FEV1 and the baseline mPAP or PVR, but both parameters
significantly correlated with the baseline SpO2.
Patients’ PH-target-therapy initiated at baseline and
their maximal therapy during the observational period is
shown in Table 2. Most patients were treated with PDE5I,
followed by ERA and inhaled prostanoids.
Table 3 shows the course of markers of disease severity
under therapy: the NYHA improved significantly from 3.5
(3; 4) at baseline to 3 (2; 4) at 3 months and 3 (2; 3.5) at
6 months (p = .020 and .008). After 1 and after 2 years
instead, the values returned to baseline. Figure 2 visualizes
changes in NYHA. The 6MWD test increased significantly
from 373 m (236; 452) at baseline to 395 m (339; 472) after
three months to 414 m (285; 492) after 6 months and to 396
m (308; 497) at 12 months (p = .005, .006, .011). After
2 years, the median was insignificantly higher compared to
baseline 434 (277; 508). Changes of the 6MWD are shown
in Fig. 3.
The SpO2 did not change under therapy, whereas the
peak-exercise SpO2 decreased to 83 (76; 88, p = .014)
after 3 months, 81 (76; 87, p = .014) after 6 months, 82
(80; 88.5, p = .116) after 1 year and 83.5 (73; 89.5,
p = .039) after 2 years (Fig. 4). Heart rate, QoL, NT-pro-
BNP and tricuspid pressure gradient did not change.
Fig. 1 Patient flow. COPD chronic obstructive pulmonary disease,
wedge pressure pulmonary artery occlusion pressure. Target therapy:
parenteral prostanoids, endothelin receptor antagonists (ERA) and
phosphodiesterase-5 inhibitors (PDE5I)
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Two patients stopped therapy with ERA. 1 pre-treated
with sildenafil after 1 month in lack of efficacy and
worsening leg oedema, 1 was switched to PDE-5 inhibitor
after 3 months in lack of efficacy. The later was thereafter
well supported until now (4 years). Three patients stopped
therapy with PDI-5 inhibitors after a mean time of 1.6
(1–3) months due to lacking efficacy. All had been pre-
treated (2 with ERA, 1 with inhaled iloprost).
We found a positive correlation between the mPAP and
PVR at baseline and the change in the 6MWD after
3 months (p = .01, R = .514 and p = .005, R = .563).
The changes in 6MWD over time did not correlate with
other baseline parameters.
During the median follow-up of 5.9 (2.3; 8.4) years, 10
patients died [after 3.1 (2.3; 4.3) years], 2 patients were
transplanted [after 2.7 (1.7; 3.6) years], and two were lost
to follow-up [after 3.3 (2.2; 4.4) years]. Kaplan–Meier
survival analysis shows that patients with an mPAP
C40 mmHg (14 patients) had worse transplant-free sur-
vival compared to patients with lower mPAP (p = .026,
Fig. 5). The transplant-free survival of patients with a
baseline 6MWD \370 m (14 patients) was significantly
worse compared to patients with better 6MWD (p = .026,
Fig. 6). Additionally, patients with a resting SpO2 \92 %
(p = .02, 13 patients) and with a peak-exercise SpO2
Table 1 Baseline characteristics of patients with chronic obstructive
pulmonary disease and pulmonary hypertension
Number (%) median
(IQR1; IQR3)
Total number of patients 27 (100)
Females 7 (26)
Age (years) 70 (60; 76)
BMI (kg/m2) 26 (24; 30)
Current smokers 5/26 (19)
Past smokers 21/26 (81)
Peak years smoked until baseline 40 (5; 50)
Peak years total 40 (5; 50)
NYHA functional class II/III/IV 3/9/12 (12.5/37.5/50)
6 min walk distance (m) 373 (236; 452)
Resting peripheral oxygen saturation
(%)
92 (86; 94)
Peak exercise peripheral oxygen
saturation (%)
87 (79; 91)
Resting heart rate (min-1) 83 (76; 93)
Peak exercise heart rate (min-1) 112 (101; 123)
COPD severity by GOLD stage I/II/III/
IV
6/12/6/3 (22/44.5/22/11.5)
Pulmonary function tests (% predicted)
Forced expiratory volume in 1 s
(FEV1 % predicted)
60 (46; 78)
Forced vital capacity (FVC % predicted) 84 (63; 105)
FEV1/FVC 57 (50.5; 64)
Total lung capacity (% predicted) 103 (90; 116)
Residual volume (% predicted) 127 (105; 189)
Carbon monoxide diffusion capacity (%
predicted)
42 (36; 59)
Emphysema at thoracic computed
tomography
23/25 (92)
Pulmonary hemodynamics
Mean pulmonary artery pressure
(mmHg)
39 (32; 44)
Cardiac index [(l/min m2)] 2.4 (2.2; 3.1)
Pulmonary vascular resistance (dyn s/
m5)
420 (357; 529)
Right atrial pressure (mmHg) 7 (5; 9)
Pulmonary artery occlusion pressure
(mmHg)
11 (9; 12)
Tricuspid pressure gradient by
echocardiography (mmHg)
57.5 (45.75; 69.25)
Haemoglobin (g/l) 15 (14; 16)
NT-pro-BNP (ng/l) 653 (159; 1,194)
COPD target therapies
Inhaled bronchodilators (long acting
beta agonist)
17/27 (63)
Inhaled bronchodilators (long acting
muscarinic antagonist)
11/25 (44)
Inhaled corticosteroids 15/27 (56)
Oral anticoagulation 24/27 (89)
Table 1 continued
Number (%) median
(IQR1; IQR3)
Supplemental oxygen 16/27 (60)
BMI body mass index, NYHA new york heart association, COPD
chronic obstructive pulmonary disease, GOLD global initiative for
chronic obstructive pulmonary disease, NT-pro-BNp N-terminal pro
b-type natriuretic peptide
Table 2 Pulmonary hypertension- target therapies started at baseline
and maximal therapy
Number (%)
PH-target therapies started at baseline
Prostanoid inhaled 5/27 (18.5)
ERA (endothelin receptor antagonist) 8/27 (30)
PDE5I (phosphodiesterase type 5 inhibitor) 14/27 (52)
Maximal PH-target therapies over whole period
Prostanoid inhaled 10/27 (37)
Prostanoid subcutaneous 2/27 (7.5)
Prostanoid intravenous 3/27 (11.5)
ERA (endothelin receptor antagonist) 15/27 (55.5)
PDE5I (phosphodiesterase type 5 inhibitor) 25/27 (93)
990 Lung (2014) 192:987–995
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\87 % (p = .012, 11 patients) had worse transplant-free
survival. Transplant-free survival was not different
according to GOLD stages or therapies. Cox regression
revealed that the 6MWD was the only predictor of trans-
plant-free survival (b = .006, p = .039) whereas age,
FEV1 (b = .012, p = .51), mPAP (b = .078, p = .08),
PVR (b = .003, p = .07) and SpO2 (b = -.128,
p = .126) were not.
Discussion
In this retrospective study in highly selected patients with
severe PH-COPD treated at a specialized PH-center, we
found that pulmonary selective vasodilator PH-target
therapy improved functional class and 6MWD, with sus-
tained improvements over 1 year. Event-free survival was
better with better hemodynamics, exercise performance
and blood oxygenation, but was not influenced by airflow
limitation.
One of the complications of COPD is that patients may
develop PH. However, the epidemiology of PH-COPD is
incompletely known and vastly varies according to the
setting (ambulatory patients, regional hospitals, intensive
care units, tertiary care centres with specialized units) [6,
9]. In advanced COPD before lung volume reduction sur-
gery or transplantation, a PH prevalence of [50 % was
found [10, 16]. The prevalence of PH-COPD differed by
GOLD stages with 5, 27 and 53 % for stages II, III and IV
[17]. PH in COPD is prognostically important; however,
RCT for PH-therapy for these patients are lacking [6, 9,
12]. In the present retrospective analysis of PH-target
therapy in a highly selected collective of patients, we found
that functional class and the 6MWD improved for up to 2
years. The resting SpO2 was unaffected by therapy whereas
peak exercise SpO2 decreased. These findings are in line
with a RCT in 37 patients with PH-COPD, who were
treated with sildenafil, which found an improved exercise
performance and a reduction of mPAP in patients with
severe PH-COPD under PDE5I-therapy [18]. However,
other studies reached contradictive results. Lange et al.
recently described a better survival in a retrospective
cohort of treated PH-COPD, but no effect of therapy on the
exercise capacity [19]. Blanco et al. investigated the effect
of sildenafil given for 3 months in addition to training to
COPD patients with mild PH at echocardiography [20].
The improvements under training were similar in the sil-
denafil- and placebo-treated groups with similar changes in
oxygenation and quality of life [20]. Others have shown
that the increase of mPAP during exercise was attenuated
by sildenafil; however, the exercise capacity did not
improve [21]. It is important to note that the latter study
analysed data of 18 COPD patients among whom just 5 hadT
a
b
le
3
C
o
u
rs
e
o
f
ch
ar
ac
te
ri
st
ic
s
u
n
d
er
th
er
ap
y
C
h
ar
ac
te
ri
st
ic
s
3
m
o
n
th
s
n
p
v
al
u
e
6
m
o
n
th
s
n
p
v
al
u
e
1
2
m
o
n
th
s
n
p
v
al
u
e
2
4
m
o
n
th
s
n
p
v
al
u
e
n
n
n
N
Y
H
A
fu
n
ct
io
n
al
cl
as
s
3
(2
;
4
)
2
3
0
.0
2
0
3
(2
;
3
.5
)
1
7
0
.0
0
8
3
(4
;
2
)
2
1
0
.4
2
9
3
(2
;
4
)
1
5
0
.6
5
5
6
m
in
w
al
k
d
is
ta
n
ce
(m
)
3
9
5
(3
3
8
.5
;
4
7
2
)
2
5
0
.0
0
5
4
1
4
(2
8
5
;
4
9
2
)
1
9
0
.0
0
6
3
9
6
(3
0
8
;
4
9
7
)
2
3
0
.0
1
1
4
3
4
(2
7
7
;
5
0
8
)
1
6
0
.1
6
3
B
o
rg
sc
al
e
4
(4
;
5
)
2
3
0
.3
0
3
4
(4
;
5
)
1
7
0
.3
1
5
4
.5
(4
;
6
.2
5
)
2
2
0
.7
3
6
5
(4
;
6
)
1
6
0
.9
7
1
R
es
ti
n
g
p
er
ip
h
er
al
o
x
y
g
en
sa
tu
ra
ti
o
n
(%
)
9
0
(8
4
;
9
5
)
2
2
0
.2
8
6
9
0
(8
7
.5
;
9
4
)
1
7
0
.7
7
5
9
1
(8
6
.5
;
9
4
)
2
1
0
.3
5
8
8
9
(8
6
;
9
1
)
1
5
0
.1
5
6
P
ea
k
ex
er
ci
se
p
er
ip
h
er
al
o
x
y
g
en
sa
tu
ra
ti
o
n
(%
)
8
3
(7
5
.5
;
8
8
)
2
2
0
.0
1
4
8
1
(7
6
;
8
7
)
1
7
0
.0
1
4
8
2
(8
0
;
8
8
.5
)
2
1
0
.1
1
6
8
3
.5
(7
3
;
8
9
.5
)
1
6
0
.0
3
9
R
es
ti
n
g
h
ea
rt
ra
te
(m
in
-
1
)
8
5
(8
0
.5
;
9
2
.5
)
2
1
0
.4
0
8
8
4
(7
4
.5
;
1
0
4
)
1
6
0
.9
7
9
8
4
(7
7
;
9
4
)
2
1
0
.6
8
9
8
4
(7
2
.5
;
9
5
)
1
6
0
.2
7
2
P
ea
k
ex
er
ci
se
h
ea
rt
ra
te
(m
in
-
1
)
1
2
0
(1
0
6
;
1
3
6
)
2
1
0
.0
5
3
1
2
0
(1
0
5
;
1
3
1
.5
)
1
7
0
.0
6
3
1
2
1
(1
0
2
;
1
3
2
.5
)
2
1
0
.1
0
4
1
1
6
(1
0
2
;
1
3
4
)
1
6
0
.1
0
0
L
H
F
Q
to
ta
l
3
7
(2
0
;
5
9
.5
)
1
3
0
.0
5
8
3
8
(2
8
;
5
2
)
1
1
*
3
6
(2
3
.5
;
4
8
)
1
3
0
.3
6
7
1
8
.5
(6
;
3
1
)
8
*
L
H
F
Q
p
h
y
si
ca
l
su
b
sc
o
re
1
8
(1
1
;
2
6
)
1
3
0
.4
4
0
2
0
(1
5
;
2
4
)
1
1
*
1
9
(1
4
.5
;
2
2
)
1
3
0
.5
0
4
1
0
.5
(4
.2
5
;
1
7
)
8
*
L
H
F
Q
em
o
ti
o
n
al
su
b
sc
o
re
6
(3
;
1
4
)
1
3
0
.1
5
6
5
(2
;
1
3
)
1
1
*
5
(2
;
1
3
)
1
3
0
.5
0
2
1
(0
;
4
.5
)
8
*
N
T
-p
ro
-B
N
P
(n
g
/l
)
5
9
4
(1
6
7
;
1
,1
7
8
)
1
8
0
.0
7
8
5
2
5
(1
9
8
;
1
,3
4
0
)
1
2
*
2
9
4
(1
4
8
;
1
,4
5
0
)
1
9
0
.9
3
8
7
6
9
(1
8
4
;
1
,9
5
1
)
1
2
*
T
ri
cu
sp
id
p
re
ss
u
re
g
ra
d
ie
n
t
(m
m
H
g
)
4
5
(4
3
.5
;
6
0
.5
0
)
2
4
0
.1
8
1
5
0
.5
(3
9
;
6
6
)
8
*
D
at
a
g
iv
en
as
m
ed
ia
n
(q
u
ar
ti
le
s)
N
Y
H
A
n
ew
y
o
rk
h
ea
rt
as
so
ci
at
io
n
,
L
H
F
Q
th
e
m
in
n
es
o
ta
li
v
in
g
w
it
h
h
ea
rt
fa
il
u
re
q
u
es
ti
o
n
n
ai
re
(h
ig
h
er
v
al
u
es
as
so
ci
at
ed
w
it
h
w
o
rs
e
q
u
al
it
y
o
f
li
fe
),
N
T
-p
ro
-B
N
p
N
-t
er
m
in
al
p
ro
b
-t
y
p
e
n
at
ri
u
re
ti
c
p
ep
ti
d
e
*
D
at
a
av
ai
la
b
le
fo
r
le
ss
th
an
1
3
p
at
ie
n
ts
,
h
en
ce
th
e
p
v
al
u
es
ar
e
n
o
t
d
is
p
la
y
ed
Lung (2014) 192:987–995 991
123
PH. Others showed that exercise capacity and stroke vol-
ume did not improve under sildenafil in a collective of
COPD patients in whom not all had PH [22]. In another
COPD-collective without resting PH, exercise capacity was
not increased by sildenafil but the gas exchange and QoL
were impaired under therapy along with more adverse
events [23]. There are few studies analysing the effect of
bosentan in patients with COPD, and the results seem to be
controversial. One study showed a positive effect of bos-
entan in patients with PH-COPD [24], the therapy seemed
to stop the progressive increase of mPAP and PVR.
Another study found no improvement in exercise capacity,
but deterioration of hypoxemia and functional status [25].
Of note, this study included patient with COPD without or
only mild PH as assessed by echocardiography and not
RHC [25]. Thus, the heterogeneity of response to PH-target
Fig. 2 New York Heart
Association functional class
(NYHA): course under therapy.
Data given as percent.
N = number of patients
assessed
Fig. 3 Evolution of the 6 min
walk distance in metres under
therapy. Data given as median
(quartiles). *p \ .05.
N = number of patients
assessed
992 Lung (2014) 192:987–995
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therapy might be due to patients’ selection and the presence
of relevant PH.
We analysed the development of SpO2 during therapy at
rest and at peak exercise in the 6MWD test. We found that
resting SpO2 did not change under PH-target therapy,
whereas peak exercise desaturation increased along with an
increased exercise capacity. Thus, our results may support
an increased ventilation–perfusion mismatch at peak
exercise however along with an increased exercise capacity
potentially due to a decreased RV afterload. A study
investigating the acute effect of sildenafil during exercise
in PH-COPD showed a reduced mPAP and PaO2 at rest
Fig. 4 Peripheral oxygen
saturation: comparison between
rest and peak exercise oxygen
saturation at baseline and under
therapy after 3, 6, 12,
24 months. 95 % confidence
intervals, data given as median,
N = number of patients
assessed
Fig. 5 Kaplan–Meier survival plots are shown for patients with mean
pulmonary artery pressure of [40 and \40 mmHg. N = number of
patients assessed
Fig. 6 Kaplan–Meier survival plots are shown for patients with a
6 min walk distance \370 and [370 m. N = number of patients
assessed
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under therapy; however, only the mPAP further decreased
with exercise but not the PaO2 [26]. In regard to prosta-
noids contradictory effects on ventilation–perfusion mis-
match were reported. In a study investigating 26 patients
with exacerbated COPD, prostaglandin E1 given intrave-
nously (IV) decreases mPAP without worsening blood
gases [27]. On the other hand, in a placebo-controlled trial
in 16 COPD patients with acute respiratory failure, PVR
reduction under IV-prostanoids was only temporary and
accompanied by a significant fall in SpO2 [28]. Similar
unfavourable effects of IV-prostanoids were found by
others [29, 30]. In our cohort, only 3 patients received IV-
prostanoid as rescue therapy. The first of these 3 patients
was transplanted after 4.6 year, the second died after
2.6 years and the third survives for 5 years now. Five
patients in our cohort were treated with inhaled iloprost.
Inhaled iloprost potentially acts preferentially in well-
ventilated regions of the lung, thereby reducing PH with
less effect ventilation–perfusion mismatch [31]. Others did
not find an improvement of exercise capacity and showed
that the oxygenation at rest deteriorated [32]. Since results
of PH-target therapies in PH-COPD are so controversial,
there is an obviously need for further and more in depth
studies in collectives of COPD patients with relevant PH
with exact characterization of hemodynamics by right heart
catheterisation, gas exchange and airflow limitation.
In our study, we found a marginally insignificant
improvement in QoL (p = .058) after 3 months of treat-
ment. Unfortunately, in our retrospective analysis not all
patients did have regular QoL assessments. However, this
important patient-centered outcome should be assessed in
future, well-performed trials.
PH-COPD is associated with worse survival [6, 11,
12]. This could be confirmed in our study, as patients
with a mPAP[40 mmHg had a worse event-free survival.
Similarly, patients with 6MWD \370 m and low resting
or peak-exercise SpO2, but not patients with worse GOLD
stages had worse event-free survival. This may indicate
that pulmonary hemodynamics and impaired blood oxy-
genation are prognostically more important than mere
airflow limitation in this COPD-collective with marked
PH and thus strengthen the need for effective therapies to
improve PH without affecting gas exchange in this
potentially vast collective. Of note, most of these patients
had a relatively good GOLD stage, this might be the
reason why we did not found a prognostic relevance of
FEV1 in this collective.
The only parameter which predicted the patients’ event-
free survival in cox regression was the 6MWD at baseline,
but not the change in 6MWD or other parameters. Other
studies have emphasized the importance of exercise
capacity as outcome parameter in COPD, e.g. Pinto-Plata
et al. showed that the 6WMD in patient with severe COPD
is a better predictor of mortality than the degree of
obstruction, BMI and associated comorbidities [33, 34].
Our study has the following limitations: As this is a
retrospective data analysis, not all patients had regular
follow-up available at each time-point and thus, we do not
know whether the results would have been different if all
patients would have had every outcome. The retrospective
design is also limited by potential selection and referral
bias: Our PH-COPD cohort was retrieved from a specialist
PH-outpatient clinic. This might explain why the mPAP
was relatively high and thus the results are not transferable
to COPD patients with mild or only exercise-induced PH.
In addition, our study was too small to look at the different
PH-target therapy classes separately. Accordingly, we are
not able to draw inference on these aspects and it may well
be that one therapy outreaches another. Despite these
drawbacks, in lack of RCTs in the field, we believe that it is
important to collect as much information as possible on the
effect of PH-target therapy in selected PH-COPD collec-
tives until data from well-designed RCTs get available.
Conclusions
In this selected cohort of patients with severe PH-COPD,
PH-target vasodilator therapy did improve NYHA func-
tional class and 6MWD without worsening resting SpO2
for up to 1 year. Poor exercise capacity, SpO2 and high
mPAP at baseline were associated with shortened trans-
plant-free survival but not worse airflow obstruction. The
baseline 6MWD was the only independent predictor of
survival.
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